Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis
Brief Summary: The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (TCS).


Options:
A: Arm Label: Betamethasone-17-valerat + placebo ointment; Type: EXPERIMENTAL; Interventions: Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo | Arm Label: Tacrolimus ointment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Protopic, tacrolimus ointment 0.1% | Intervention Type: DRUG; Name: Betnovate, betamethasone dipropionate ointment 0.1% and placebo; Assigned to Arm(s): Betamethasone-17-valerat + placebo ointment | Intervention Type: DRUG; Name: Protopic, tacrolimus ointment 0.1%; Assigned to Arm(s): Tacrolimus ointment
B: Arm Label: VC Period: Vehicle Cream BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle Cream | Arm Label: VC Period: Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib Cream | Arm Label: VC Period: Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib Cream | Arm Label: LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib Cream | Arm Label: LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib Cream | Arm Label: LTS Period: Ruxolitinib 0.75% Cream; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib Cream | Arm Label: LTS Period: Ruxolitinib 1.5% Cream; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib Cream | Intervention Type: DRUG; Name: Ruxolitinib Cream; Assigned to Arm(s): LTS Period: Ruxolitinib 0.75% Cream, LTS Period: Ruxolitinib 1.5% Cream, LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID, LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID, VC Period: Ruxolitinib 0.75% Cream BID, VC Period: Ruxolitinib 1.5% Cream BID | Intervention Type: DRUG; Name: Vehicle Cream; Assigned to Arm(s): VC Period: Vehicle Cream BID
C: Arm Label: AN2898 ointment, 1%, vs. ointment vehicle; Type: EXPERIMENTAL; Interventions: Drug: AN2898 ointment, 1%, Drug: AN2898 ointment vehicle | Arm Label: AN2728 ointment, 2%, vs. ointment vehicle; Type: EXPERIMENTAL; Interventions: Drug: AN2728 ointment, 2%, Drug: AN2728 ointment vehicle | Intervention Type: DRUG; Name: AN2728 ointment, 2%; Assigned to Arm(s): AN2728 ointment, 2%, vs. ointment vehicle | Intervention Type: DRUG; Name: AN2898 ointment, 1%; Assigned to Arm(s): AN2898 ointment, 1%, vs. ointment vehicle | Intervention Type: DRUG; Name: AN2898 ointment vehicle; Assigned to Arm(s): AN2898 ointment, 1%, vs. ointment vehicle | Intervention Type: DRUG; Name: AN2728 ointment vehicle; Assigned to Arm(s): AN2728 ointment, 2%, vs. ointment vehicle
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pimecrolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Topical corticosteroids | Intervention Type: DRUG; Name: Pimecrolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Topical corticosteroids; Assigned to Arm(s): 2

Answer: D